Healthy Blood Vessels II – F5, F2 and MTHFR Genetic Test

Product detailed description

The Healthy Blood Vessels II Genetic Test (F5, F2 and MTHFR) analyzes inherited genetic variants associated with blood clotting and homocysteine metabolism. Certain genetic changes may increase susceptibility to abnormal blood clot formation, potentially contributing to conditions such as deep vein thrombosis (DVT) and pulmonary embolism.

The test focuses on three genes – F5, F2 and MTHFR. The F5 and F2 genes play essential roles in blood coagulation, and specific variants are recognized genetic risk factors for venous thrombosis. The MTHFR gene is involved in folate (vitamin B9) and homocysteine metabolism, although common MTHFR variants are not considered established risk factors for venous thrombosis.

What does the genetic test analyze?

• F5 gene (Factor V Leiden) – a genetic variant associated with an increased tendency to develop blood clots.

• F2 gene (prothrombin) – a genetic variant linked to increased venous thrombosis risk.

• MTHFR gene – genetic variants involved in folate and homocysteine metabolism.

• Inherited clotting predispositions – information about selected genetic risk factors associated with venous thromboembolism.

Who may benefit from this genetic test?

• Individuals with a family history of venous thrombosis or known inherited thrombophilia.

• Patients for whom a healthcare professional has recommended genetic testing following a thrombotic event.

• Individuals being evaluated for inherited thrombophilia in the context of other risk factors.

• People interested in genetic factors related to blood coagulation and homocysteine metabolism.

What can the results reveal?

The F5, F2 and MTHFR genetic test identifies selected inherited variants associated with blood clotting pathways and folate metabolism.

Identifying relevant F5 or F2 variants may help healthcare professionals assess an individual's predisposition to venous thrombosis alongside personal and family medical history and other factors such as age, smoking, pregnancy, hormonal medication, or prolonged immobility.

Important: Carrying a risk-associated variant does not mean that thrombosis will necessarily occur, and a negative result does not eliminate the possibility of blood clots. Common MTHFR variants are not considered reliable markers of thrombosis risk under current clinical guidelines. Genetic testing does not replace comprehensive hematological evaluation, and testing decisions and results should be reviewed by a healthcare professional.